Skye Bioscience (SKYE) Shares Outstanding (2012 - 2026)
Skye Bioscience (SKYE) posted quarterly Shares Outstanding (Entity) of $35.1 million for Q1 2026, down 11.41% year-over-year from $39.7 million in Q1 2025, and up 5.24% quarter-over-quarter from $33.4 million in Q4 2025.
Skye Bioscience (SKYE) Shares Outstanding (2012 - 2026) Analysis & Trends
Skye Bioscience (SKYE) has reported Shares Outstanding (Entity) for 15 consecutive years, with $35.1 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Shares Outstanding (Entity) fell 11.41% year-over-year to $35.1 million; the TTM figure through Mar 2026 stood at $35.1 million (down 11.41% YoY), while the FY2025 annual figure was $33.4 million, up 7.76% from the prior year.
- Shares Outstanding (Entity) advanced to $35.1 million in Q1 2026 per SKYE's latest filing, from $33.4 million in the prior quarter.
- Across five years, Shares Outstanding (Entity) topped out at $39.7 million in Q3 2025 and bottomed at $2.0 million in Q1 2022.
- Historically, Shares Outstanding (Entity) has averaged $20.9 million across 5 years, with a median of $28.1 million in 2024.
- Annual changes were most pronounced in 2024 — Shares Outstanding (Entity) soared 895.04% — and 2026, when it retreated 11.41%.
- Skye Bioscience's Shares Outstanding (Entity) stood at $2.2 million in 2022, then surged by 215.43% to $7.0 million in 2023, then jumped by 342.11% to $31.0 million in 2024, then grew by 7.76% to $33.4 million in 2025, then increased by 5.24% to $35.1 million in 2026.
- Business Quant data shows SKYE's Shares Outstanding (Entity) at $35.1 million in Q1 2026, $33.4 million in Q4 2025, and $39.7 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Shares Outstanding (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 253.70 Mn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 102.80 Mn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 62.19 Mn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 398.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 111.58 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 133.61 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 217.35 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 445.06 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 241.70 Mn |
| 10 | Skye Bioscience | 11.17 Mn | 11.17 Mn | - | 39.69 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 39.68 Mn |
| Dec 31, 2025 | 39.66 Mn |
| Sep 30, 2025 | 39.67 Mn |
| Jun 30, 2025 | 39.66 Mn |
| Mar 31, 2025 | 39.65 Mn |
| Dec 31, 2024 | 36.49 Mn |
| Sep 30, 2024 | 38.82 Mn |
| Jun 30, 2024 | 38.67 Mn |
| Mar 31, 2024 | 28.00 Mn |
| Dec 31, 2023 | 7.01 Mn |
| Sep 30, 2023 | 7.88 Mn |
| Jun 30, 2023 | 3.89 Mn |
| Mar 31, 2023 | 3.77 Mn |
| Dec 31, 2022 | 2.22 Mn |
| Sep 30, 2022 | 1.98 Mn |
| Jun 30, 2022 | 1.98 Mn |
| Mar 31, 2022 | 1.98 Mn |
| Dec 31, 2021 | 1.63 Mn |
| Sep 30, 2021 | 1.65 Mn |
| Jun 30, 2021 | 1.51 Mn |